<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37083167</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0392-856X</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Clinical and experimental rheumatology</Title><ISOAbbreviation>Clin Exp Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Pulmonary hypertension in juvenile-onset systemic lupus erythematosus: a case series.</ArticleTitle><Pagination><StartPage>1934</StartPage><EndPage>1939</EndPage><MedlinePgn>1934-1939</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.55563/clinexprheumatol/pye2t3</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Systemic lupus erythematosus (SLE) is a rare multisystem autoimmune disorder with a variable clinical phenotype. Pulmonary hypertension (PHTN) is a recognised (and not uncommonly asymptomatic) complication of the condition with an associated poor prognosis in adults. It is relatively rare in juvenile-onset SLE (JSLE).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We present a retrospective descriptive case series of four female children aged 4 to 15 years at presentation of JSLE and aged 8 to 27 years at time of diagnosis of PHTN from the United Kingdom. All cases were identified through the UK JSLE Cohort Study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 665 children with JSLE in the UK cohort study to date (data from 2006-2020), four (0.6%) were identified as having PHTN. 3/4 of the PHTN cases presented with cardiovascular symptoms and / or signs at presentation.3/4 were treated with Rituximab and had a good long-term outcome. Shared clinical features include high baseline disease activity scores.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">JSLE has a high associated cardiovascular morbidity and mortality and early identification of treatable complications such as PHTN is vital. We suggest that children with high baseline disease activity scores and those presenting with cardiovascular symptoms and signs are most likely to have concurrent PHTN. Routine echocardiography is an effective screening tool and should be used as part of a standard diagnostic work-up.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Platt</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Paediatric Nephrology, Bristol Royal Hospital for Children, Bristol, UK. caroline.platt2@nhs.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Longthorpe</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sit</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Paediatric Nephrology, Evelina London Children's Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marks</LastName><ForeName>Stephen D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>NIHR Great Ormond Street Hospital Biomedical Research Centre, University College London Great Ormond Street Institute of Child Health, London, and Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond Street, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harmer</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Paediatric Nephrology, Southampton Children's Hospital, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciurtin</LastName><ForeName>Coziana</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Paediatric Rheumatology, University College London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramanan</LastName><ForeName>Athimalaipet V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beresford</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Women's and Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, and Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>UK JSLE Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Clin Exp Rheumatol</MedlineTA><NlmUniqueID>8308521</NlmUniqueID><ISSNLinking>0392-856X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006976" MajorTopicYN="Y">Hypertension, Pulmonary</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>29</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>21</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>21</Day><Hour>7</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37083167</ArticleId><ArticleId IdType="doi">10.55563/clinexprheumatol/pye2t3</ArticleId><ArticleId IdType="pii">19235</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>